InDex Pharmaceuticals AB

InDex Pharmaceuticals AB

InDex Pharmaceuticals is a pharmaceutical development company focused on immunological diseases with a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, currently undergoing evaluation in the phase III study CONCLUDE as a novel treatment for moderate to severe ulcerative colitis, a chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, known as DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

InDex Pharmaceuticals, founded in 2000, is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

In summary, InDex Pharmaceuticals is a promising pharmaceutical company with a focus on addressing unmet needs in immunological diseases, particularly through its lead asset cobitolimod and its proprietary DIMS platform.